Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cytodyn Inc (CYDY)

Cytodyn Inc (CYDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cytodyn Inc 1111 MAIN STREET SUITE 660 VANCOUVER WA 98660 USA

P: 360-980-8524

Description:

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.

Key Statistics

Overview:

Market Capitalization, $K 1,581,536
Shares Outstanding, K 644,210
Annual Sales, $ 0 K
Annual Net Income, $ -154,670 K
60-Month Beta -0.59
% of Insider Shareholders 7.80%
% of Institutional Shareholders 0.14%
Float, K 593,962
% Float 92.20%

Growth:

1-Year Return -30.35%
3-Year Return 367.62%
5-Year Return 245.92%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 10/08/21
Earnings Per Share ttm -0.12
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year -20.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CYDY Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -2.90
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -119.81%
Profit Margin % 0.00
Net Margin % N/A
Debt/Equity N/A
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 0.00
Interest Coverage -6.91
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar